Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Vanderhoeven, Fiorella, Redondo, Analía Lourdes, Martinez, Ana Laura, Vargas-Roig, Laura María, Sanchez, Angel Matias, Flamini, Marina Inés
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995169/
https://ncbi.nlm.nih.gov/pubmed/29899874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25480
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi